Synonym
AU 1421, AU1421, AU-1421
IUPAC/Chemical Name
5-Methyl-2-(2-(1-naphthyl)ethenyl)-4-piperidinopyridine hydrochloride
InChi Key
FIRAEJACZMKMQE-USGGBSEESA-N
InChi Code
1S/C23H24N2.ClH/c1-18-17-24-21(16-23(18)25-14-5-2-6-15-25)13-12-20-10-7-9-19-8-3-4-11-22(19)20;/h3-4,7-13,16-17H,2,5-6,14-15H2,1H3;1H/b13-12-;
SMILES Code
Cc1cnc(cc1N2CCCCC2)/C=C\c3cccc4c3cccc4.Cl
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
364.92
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Nagamune H, Fukushima Y, Takada J, Yoshida K, Unami A, Shimooka T, Terada H. The lipophilic weak base (Z)-5-methyl-2-[2-(1-naphthyl)ethenyl]-4-piperidinopyridine (AU-1421) is a potent protonophore type cationic uncoupler of oxidative phosphorylation in mitochondria. Biochim Biophys Acta. 1993 Mar 1;1141(2-3):231-7. PubMed PMID: 8382953.
2: Fukushima Y, Asano S, Takada J. K(+)-site-directed pyridine derivative, AU-1421, activates hydrolysis of the K(+)-sensitive phosphoenzyme of sarcoplasmic reticulum Ca(2+)-ATPase and inactivates that of K(+)-transporting ATPases. Biochim Biophys Acta. 1992 Apr 29;1106(1):71-6. PubMed PMID: 1533792.
3: Hioki Y, Takada J, Hidaka Y, Yano M. Environmental differences of a pyridine derivative (AU-1421)-access sites between (H+,K+)-ATPase and (Na+,K+)-ATPase. J Pharmacobiodyn. 1991 Mar;14(3):170-5. PubMed PMID: 1652636.
4: Takada J, Hioki Y, Yano M. (Z)-5-methyl-2-[2-(1-naphthyl)ethenyl]-4-piperidinopyridine (AU-1421), calcium ions and ethylenediamine as the K(+)-site directed probe for Na+/K(+)-ATPase. Biochim Biophys Acta. 1990 Nov 15;1041(2):123-8. PubMed PMID: 2176105.
5: Takada J. Reversible inhibition of sodium and potassium-dependent adenosine triphosphatase by the pyridine derivative, AU-1421 during turnover cycle. Biochem Pharmacol. 1990 Oct 1;40(7):1527-31. PubMed PMID: 2171532.
6: Hioki Y, Takada J, Hidaka Y, Takeshita H, Hosoi M, Yano M. A newly synthesized pyridine derivative, (Z)-5-methyl-2-[2-(1-naphthyl)ethenyl]-4-piperidinopyridine hydrochloride (AU-1421), as a reversible gastric proton pump inhibitor. Arch Int Pharmacodyn Ther. 1990 May-Jun;305:32-44. PubMed PMID: 2173509.
